KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Non-Current Deffered Revenue: 2010-2021

Historic Non-Current Deffered Revenue for Emergent BioSolutions (EBS) over the last 9 years, with Dec 2021 value amounting to $4.7 million.

  • Emergent BioSolutions' Non-Current Deffered Revenue fell 88.76% to $5.9 million in Q1 2022 from the same period last year, while for Mar 2022 it was $5.9 million, marking a year-over-year decrease of 88.76%. This contributed to the annual value of $4.7 million for FY2021, which is 91.53% down from last year.
  • Per Emergent BioSolutions' latest filing, its Non-Current Deffered Revenue stood at $4.7 million for FY2021, which was down 91.53% from $55.5 million recorded in FY2020.
  • In the past 5 years, Emergent BioSolutions' Non-Current Deffered Revenue registered a high of $85.6 million during FY2019, and its lowest value of $4.7 million during FY2021.
  • Its 3-year average for Non-Current Deffered Revenue is $48.6 million, with a median of $55.5 million in 2020.
  • Per our database at Business Quant, Emergent BioSolutions' Non-Current Deffered Revenue soared by 261.27% in 2018 and then slumped by 91.53% in 2021.
  • Emergent BioSolutions' Non-Current Deffered Revenue (Yearly) stood at $17.3 million in 2017, then skyrocketed by 261.27% to $62.5 million in 2018, then spiked by 36.96% to $85.6 million in 2019, then crashed by 35.16% to $55.5 million in 2020, then plummeted by 91.53% to $4.7 million in 2021.